Management ChangeMay 4, 2026, 04:03 PM
Damora Therapeutics CFO Lori Firmani Departs; Brian Burkavage Appointed
AI Summary
Damora Therapeutics announced that Lori Firmani ceased serving as Chief Financial Officer, principal financial officer, and principal accounting officer, effective May 1, 2026. She will receive separation benefits, including a lump sum payment and full equity award acceleration, subject to a separation agreement. Concurrently, Brian Burkavage, the company's Senior Vice President, Finance, was appointed to succeed her as principal financial and accounting officer.
Key Highlights
- Lori Firmani ceased serving as Chief Financial Officer, principal financial officer, and principal accounting officer effective May 1, 2026.
- Ms. Firmani will receive separation benefits, including a lump sum for salary/bonus and a $6,000 health savings account contribution.
- All of Ms. Firmani's outstanding equity awards will be fully accelerated.
- Brian Burkavage was appointed principal financial officer and principal accounting officer, effective May 1, 2026.
- Mr. Burkavage previously served as Senior Vice President, Finance and Chief Accounting Officer at IO Biotech, Inc.
- He is a licensed Certified Public Accountant with 11 years at Ernst & Young LLP.
Price Impact
More from DMRA